Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Whitehawk Therapeutics (WHWK) over the last 5 years, with Jun 2025 value amounting to $7.6 million.

  • Whitehawk Therapeutics' Gains from Investment Securities was N/A to $7.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $7.6 million, marking a year-over-year change of. This contributed to the annual value of -$518,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Per Whitehawk Therapeutics' latest filing, its Gains from Investment Securities stood at $7.6 million for Q2 2025, which was up 6,759.48% from -$114,000 recorded in Q1 2025.
  • Whitehawk Therapeutics' 5-year Gains from Investment Securities high stood at $7.6 million for Q2 2025, and its period low was -$159,000 during Q2 2023.
  • Its 3-year average for Gains from Investment Securities is $833,851, with a median of -$121,500 in 2023.
  • In the last 5 years, Whitehawk Therapeutics' Gains from Investment Securities spiked by 1,048.11% in 2021 and then slumped by 487.10% in 2023.
  • Over the past 5 years, Whitehawk Therapeutics' Gains from Investment Securities (Quarterly) stood at $610,000 in 2021, then crashed by 71.16% to $31,000 in 2022, then slumped by 487.10% to -$120,000 in 2023, then fell by 25.83% to -$151,000 in 2024, then increased by 17.39% to $7.6 million in 2025.
  • Its Gains from Investment Securities was $7.6 million in Q2 2025, compared to -$114,000 in Q1 2025 and -$151,000 in Q4 2024.